As part of the company's strategy for market expansion, the company has today signed an agreement with a distributor in South Africa. Today, the distributor sells a leading global brand to preserve organs outside the body and keep them in optimal condition while awaiting transplantation. Glycosorb® ABO thus fits in very well with their existing product portfolio and customer network. The agreement marks the first entry of the Glycosorb® ABO product on the African continent.
In South Africa, about 240 kidney transplants are performed per year, of which about 40% are from living donors. The number of liver transplants amounts to about 70 per year. In terms of size, the market is on a par with Norway.
As a first step the distributor will register the product, a job that is estimated to take a few months.
Geert Nygaard, CEO, Glycorex Transplantation AB.
E-mail: firstname.lastname@example.org, phone: 046-286 52 30
This information is such information that Glycorex Transplantation AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on January 17, 2022 at 17.20 CET.
Brief information about the company
Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.